4th Quarter - Report — ALLERGAN USA, INC. for ALLERGAN USA, INC. (2019)

Firm

ALLERGAN USA, INC.

Client

ALLERGAN USA, INC.

Income

—

Expenses

$400,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.

Lobbyist	Covered position, as disclosed
DANIEL M HARDER	—
ROBERT W. LIVELY	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

Issues relating to tax moratoriums for medical devices.

Lobbyist	Covered position, as disclosed
DANIEL M HARDER	—
ROBERT W. LIVELY	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Office of Management & Budget (OMB)

Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.

Lobbyist	Covered position, as disclosed
DANIEL M HARDER	—
ROBERT W. LIVELY	—

Contacted: Food & Drug Administration (FDA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Copyright/Patent/Trademark CPT

Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.

Lobbyist	Covered position, as disclosed
DANIEL M HARDER	—
ROBERT W. LIVELY	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.

Lobbyist	Covered position, as disclosed
DANIEL M HARDER	—
ROBERT W. LIVELY	—

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Health Issues HCR

Proposals encouraging research and development and manufacturing of potentially life-saving treatments and ensuring patient access to improve quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases.

Lobbyist	Covered position, as disclosed
DANIEL M HARDER	—
ROBERT W. LIVELY	—

Contacted: SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.